Patients & Families

One of the goals of the NeuroNEXT Network is to benefit patients and their families by facilitating more rapid access to trials, and providing a clear answer to a clinical question in a short period of time. We accomplish this by combining efficiencies and leveraging our expansive network to get studies started more quickly, recruit patients rapidly, and ensure data accuracy for faster analysis.  The NeuroNEXT Network is changing the face of neurological research. Recent successes include: 

• NN101 SMA, a biomarker-driven study in Spinal Muscular Atrophy (SMA) recently published results in the Annals of Neurology. An accompanying editorial noted that, based in part on data obtained in the study, the FDA approved the first effective therapy for SMA, and an additional gene therapy may shortly follow.
• NN102 SPRINT-MS, a study to evaluate the safety and tolerability of Ibudilast in patients with Multiple Sclerosis (MS), recently announced very promising results in MS treatment, noting that Ibudilast demonstrated a statistically significant reduction in the rate of progression of whole brain atrophy as compared to placebo.

NeuroNEXT Projects that are currently enrolling include: 

• NN105 - an intervention to test the tolerability and safety of SRX246 in irritable subjects with early symptomatic Huntington's Disease
• NN106 - a prospective study of Cytochrom C Oxidase activity in patients with newly diagnosed Glioblastoma Multiforme tumors
• NN107 - a study evaluating the effect of AFQ056 on young children with Fragile X Syndrome
• NN108 - a study evaluating the effect of topirimate on patients with Cryptogenic Sensory Peripheral Neuropathy

Please visit the project pages to learn more about our enrolling studies and learn how to participate.